REGN Q1 2020 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.8B+33.2% YoY

Gross Profit

$1.6B85.0% margin

Operating Income

$700M38.3% margin

Net Income

$625M34.2% margin

EPS (Diluted)

$5.43

QoQ Revenue Growth

-1.9%

Cash Flow

Operating Cash Flow

$698M

Free Cash Flow

$528M

Stock-Based Comp.

$106M

Balance Sheet

Total Assets

$15.8B

Total Liabilities

$3.6B

Stockholders' Equity

$12.1B

Cash & Equivalents

$2.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.8B	$1.4B	+33.2%
Gross Profit	$1.6B	$1.1B	+35.3%
Operating Income	$700M	$480M	+45.9%
Net Income	$625M	$461M	+35.5%

Revenue Segments

Product

$1.2B100%